Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar M. P. 470003, India.
Crit Rev Ther Drug Carrier Syst. 2012;29(5):355-419. doi: 10.1615/critrevtherdrugcarriersyst.v29.i5.10.
The indispensable obligation behind the successful therapy of a disease is to deliver the effective drug/bioactive concentration with sustained release manner at the diseased organs without any exposure to the healthy tissues. Novel drug-delivery systems increase the concentration and persistence of drug at the vicinity of the target site and thereby minimize the undesired side effects of the drug to the normal tissues of body. With advances in nanotechnology, several new drug delivery approaches have become available that may fulfil the requirement of safe and effective drug therapy. Among these techniques, vesicular drug-delivery systems, particularly liposomes, are under rigorous research for their applicability to deliver FDA-approved and newer drugs. Liposomes have been widely investigated as one of the most widely used nanocarriers in cancer therapy and have shown their potential in spatial and temporal release of bioactive agents for the effective treatment of various life-threatening diseases, including cancer. Various targeted and triggered-release approaches of bioactive substances using liposomes further improve the applicability of liposomes in cancer therapeutics. Thus, keeping these points in view, the present review has been focussed on application of liposomes for development of liposome technology and its novel applications for effective cancer therapy.
成功治疗疾病背后不可或缺的义务是将有效药物/生物活性浓度以持续释放的方式递送到病变器官，而不会暴露于健康组织中。新型药物传递系统可增加目标部位附近药物的浓度和持久性，从而最大程度地减少药物对身体正常组织的不良副作用。随着纳米技术的进步，已经出现了几种新的药物输送方法，这些方法可能满足安全有效的药物治疗的要求。在这些技术中，囊泡药物传递系统，特别是脂质体，因其在将 FDA 批准的和较新的药物递送上的适用性而受到严格研究。脂质体已被广泛研究作为癌症治疗中最广泛使用的纳米载体之一，并已显示出在生物活性物质的时空释放方面的潜力，可有效治疗包括癌症在内的各种危及生命的疾病。使用脂质体对生物活性物质进行各种靶向和触发释放的方法进一步提高了脂质体在癌症治疗中的适用性。因此，考虑到这些要点，本综述重点介绍了脂质体在开发脂质体技术及其在有效癌症治疗中的新应用方面的应用。
